Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical OfficerFebruary 8, 2022 - 8:00 am
- Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001June 14, 2021 - 9:00 am
- Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by RocheOctober 7, 2020 - 7:02 am
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002August 17, 2020 - 9:00 am
Follow Us On Twitter
We are pleased to join @EmilysEntourage in #CFAwarenessMonth to unite the strengths of the #CysticFibrosis community and #CrossOutCF.
Our #scientists are committed to delivering therapies aimed at treating all people with #CF, regardless of #genotype: https://rb.gy/h7be7s